The shadow of generic challenges has consistently loomed above copyright’s blockbuster drug, Sildenafil, raising questions about the outlook of connected drug investments. While initial times saw impressive returns, the intellectual property lapse has allowed the path for discounted alternatives, likely lowering revenue and creating a real danger